Multiple myeloma, a relatively rare form of cancer, comprises only 1 to 2 percent of all cancer cases in humans, yet it represents a significant chunk, approximately 15 percent, of all hematologic malignancies. What sets the stage for this condition is a premalignant state known as monoclonal gammopathy of undetermined significance, which lurks within approximately 3 percent of individuals aged 50 and older. Over time, this precursor condition has the potential to transform into multiple myeloma and various other plasma ...
Read More
Multiple myeloma, a relatively rare form of cancer, comprises only 1 to 2 percent of all cancer cases in humans, yet it represents a significant chunk, approximately 15 percent, of all hematologic malignancies. What sets the stage for this condition is a premalignant state known as monoclonal gammopathy of undetermined significance, which lurks within approximately 3 percent of individuals aged 50 and older. Over time, this precursor condition has the potential to transform into multiple myeloma and various other plasma cell disorders, progressing at a rate of approximately 1 percent each year. This sheer prevalence, coupled with the ever-advancing landscape of medical science, has contributed to the increasing complexity surrounding the management of myeloma and other plasma cell disorders. The incorporation of genetic studies into mainstream diagnostic and treatment decision-making processes, the continual refinement of response assessment criteria, and the bewildering assortment of treatment options available have further compounded this complexity. To top it off, new therapies are being consistently introduced into the medical arsenal, and established practices such as hematopoietic stem cell transplantation have experienced paradigm shifts. In light of this intricate landscape, this book embarks on a comprehensive exploration of topics that span the spectrum of plasma cell dyscrasias. It delves into not only multiple myeloma but also monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, plasma cell leukemia, mixed cryoglobulinemia syndrome, the heavy chain diseases, POEMS syndrome, and amyloidosis. The objective of this book is twofold. Firstly, it seeks to refresh and update the knowledge of medical professionals, keeping them abreast of the latest advancements and challenges in the field of plasma cell dyscrasias. Secondly, it strives to be an accessible resource for non-professionals, offering a lucid and informative narrative that familiarizes them with the fundamental concepts underpinning these disorders. By empowering readers with a deeper understanding of plasma cell dyscrasias, this book aims to facilitate informed decision-making and promote a more engaged approach to managing these conditions. As we embark on this exploration together, we invite you to journey through the intricate world of plasma cell dyscrasias and discover the cutting-edge science and clinical insights that define this fascinating field. Dr. Bhratri Bhushan MBBS, MD (Internal medicine), DM (Medical oncology) is a consultant medical oncologist and hematologist. He has published more than one hundred books on the subjects of oncology and internal medicine and his papers have been published in renowned journals of medical literature. His works can be found at his AuthorCentral page: ...
Read Less
